Genessense

What Genessense does

Genessense is a direct-to-consumer genomic wellness brand operated by MedGenome Labs Ltd., an Indian genetic diagnostics company headquartered in Bangalore. The company offers 14+ individual genetic and epigenetic screening tests plus two bundled packages, targeting South Asian consumers with genetic risk assessments for chronic conditions including coronary artery disease, type 2 diabetes, hypertension, obesity, hereditary cancer, Parkinson's and Alzheimer's disease, age-related macular degeneration, and pharmacogenomics. All PRS-based tests are validated specifically for the South Asian population, a cohort that has historically been under-represented in global genetic studies.

The product portfolio is built on Polygenic Risk Score (PRS) methodology, Next-Generation Sequencing, and DNA methylation analysis, with tests analyzing between 1 million and 6.9 million genetic markers per condition. Notable products include Kardiogen (6.48M markers for CAD), Diabetogen (6.9M markers for T2D), Curegen Advanced (pharmacogenomics across 20 genes and 100 drugs/drug classes per CPIC guidelines), and myTrueAge (epigenetic biological age via PCGrimAge and DunedinPACE). Sample processing occurs at South Asia's largest CAP-accredited genetic testing lab, and the company has research collaborations with the Broad Institute of MIT and Harvard, NIBMG, Massachusetts General Hospital, Cambridge University, and a consortium of Indian hospitals.

Revenue is generated through one-time fees for individual tests or bundled packages (Genessense Premium, Genessense Advanced) sold exclusively through the Genessense e-commerce platform (customer.genessense.com). Free pre- and post-test genetic counseling is included. Geographic operations are limited to India — kits are not shipped internationally. The company is wholly owned by MedGenome Labs Ltd., with no external institutional investors or public listing disclosed.

Name

Genessense

Legal name

MedGenome Labs Ltd.

Website

https://genessense.com

Company type

Private

Founded year

2013

Operating status

Operating

Short description

Genessense is an India-based direct-to-consumer genomic wellness brand offering 14+ genetic and epigenetic screening tests for South Asian consumers, covering chronic disease risk, pharmacogenomics, and biological aging via its e-commerce platform.

Ownership category

akta.pro rank

Product category

Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Epigenomics & Chromatin Profiling Services (HLAGANAF)

Keywords

• Genetic screening tests
• Polygenic risk scores
• Pharmacogenomics testing
• Hereditary cancer screening
• Epigenetic age testing

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Direct-to-Consumer Genetic Testing Kits: Genessense sells genomic wellness screening kits directly to consumers through their e-commerce platform. Customers purchase individual tests (Kardiogen, Diabetogen, etc.) or bundled packages (Premium, Advanced) and pay a one-time fee for each test. Sample collection is done via saliva or blood, with results delivered digitally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Genessense sells direct-to-consumer genetic and epigenetic screening tests covering chronic disease risk (coronary artery disease, type 2 diabetes, hypertension, obesity, hypercholesterolemia, atrial fibrillation, NAFLD), neurological conditions (Parkinson's, Alzheimer's, AMD), hereditary cancer, recessive carrier status, pharmacogenomics, and biological age estimation. Tests are based on Polygenic Risk Score (PRS) methodology validated for South Asian populations, NGS for hereditary cancer, and DNA methylation analysis for epigenetic age. Customers purchase kits online, submit saliva or blood samples, and receive digital results with free pre- and post-test genetic counselling.

Product overview

Genessense is a genomic wellness screening platform offering a comprehensive portfolio of genetic and epigenetic screening tests for preventive healthcare. The offering consists of 14 individual core screening products (Kardiogen, Kardiogen Plus, Diabetogen, Hypersense, Fitgen, Lipidgen, Hepasense, Atrialgen, Visigen, Neurosense, Oncosense, Carriergen, Curegen, Curegen Advanced, myTrueAge) plus two bundled packages (Genessense Premium and Genessense Advanced). These tests use Polygenic Risk Score (PRS) methodology, Next-Generation Sequencing, and DNA methylation analysis to provide genetic risk assessments for cardiovascular diseases, metabolic conditions, neurological disorders, cancers, pharmacogenomics, and biological age estimation. All PRS-based tests are validated for the South Asian population. The platform operates through MedGenome Labs Ltd. and includes free pre- and post-test genetic counseling services.

Differentiator

Problem solved

Functional benefit

Brands

• Kardiogen: Genetic risk assessment for Coronary Artery Disease (CAD) using over 6.48 million genetic markers
• Kardiogen Plus
• Diabetogen
• Curegen Advanced
• Curegen
• Hypersense
• Fitgen
• Hepasense
• Visigen
• Neurosense
• Oncosense
• Carriergen
• Lipidgen
• myTrueAge
• Atrialgen
• Genessense Premium
• Genessense Advanced

Products and services

• Kardiogen Genetic screening for coronary artery disease risk using Polygenic Risk Score (PRS) methodology across over 6.48 million genetic markers; intended for Indian/South Asian adults seeking cardiovascular risk assessment.
• Kardiogen Plus Integrated coronary artery disease risk screening combining PRS (6.48+ million markers) with clinical parameters (age, cholesterol, blood pressure, BMI, diabetes status, smoking, lipid levels) for comprehensive CAD risk assessment.
• Diabetogen PRS-based genetic screening for Type 2 Diabetes Mellitus risk analyzing over 6.9 million genetic variations, validated for the South Asian population.
• Hypersense Genetic screening for hypertension risk analyzing over 1 million genetic markers, validated for the South Asian population.
• Fitgen Genetic screening for obesity/high BMI risk analyzing over 2 million genetic markers, validated for the South Asian population.
• Lipidgen Genetic screening for hypercholesterolemia risk analyzing over 1 million genetic markers, validated for the South Asian population.
• Hepasense Genetic screening for non-alcoholic fatty liver disease (NAFLD) risk analyzing 245,000 genetic markers, and elevated Alanine transaminase (ALT) risk analyzing 559,000 genetic markers.
• Atrialgen Genetic screening for atrial fibrillation risk analyzing 6.7 million genetic markers, validated for the South Asian population.
• Visigen Genetic screening for age-related macular degeneration (AMD) risk analyzing over 1 million genetic markers, validated for the South Asian population.
• Neurosense Genetic screening for Parkinson's disease (using PRS across 2,000+ markers) and Alzheimer's disease (using ApoE e2, e3, e4 genotypes), validated for the South Asian population.
• Oncosense Next-Generation Sequencing based screening for hereditary cancer predisposition analyzing over 60 genes covering 12 organ/tissue types.
• Carriergen Carrier screening for recessive genetic disorders analyzing more than 2,000 genes and associated phenotypes, intended for couples planning pregnancy.
• Curegen Pharmacogenomics screening assessing metabolism of up to 80 drugs/drug classes across 15 genes to evaluate individual drug response, based on CPIC guidelines.
• Curegen Advanced Advanced pharmacogenomics screening assessing metabolism of up to 100 drugs/drug classes across 20 genes to evaluate individual drug response, based on CPIC guidelines.
• myTrueAge Epigenetic screening estimating Biological Age and Pace of Aging using DNA methylation analysis at 70,000+ markers (PCGrimAge) and 17,000 markers (DunedinPACE).
• Genessense Premium Bundled genomic screening package covering genetic risk for 5 common lifestyle conditions (CAD, Type 2 Diabetes, Hypertension, Obesity, Hypercholesterolemia) and drug effectiveness (up to 80 drugs/drug classes across 15 genes).
• Genessense Advanced Comprehensive bundled health screening covering genetic risk for inherited cancer, AMD, Parkinson's, Alzheimer's, pregnancy-related carrier screening, lifestyle conditions (CAD, T2D, Hypertension, Obesity, Hypercholesterolemia) and drug effectiveness.

Quantifiable outcome

• PRS validation studies published in peer-reviewed journals including Nature, Journal of the American College of Cardiology, and Frontiers in Genetics
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• MedGenome Labs Ltd.coreOthersGenessense is powered by MedGenome Labs Ltd., India's leading genetic diagnostics and genomics research company. MedGenome provides the laboratory infrastructure, sequencing technology (Illumina NovaSeq, HiSeq X, etc.), and scientific expertise behind Genessense tests. Genessense is a flagship genomic wellness brand under MedGenome.
• Harvard (Broad Institute of MIT and Harvard)majorStrategic or Co-development PartnerCollaborated with Harvard-affiliated institutions including Broad Institute, Massachusetts General Hospital, and Cambridge University on validation studies for PRS in South Asian populations. Contributed to the landmark CAD PRS validation study published in Journal of the American College of Cardiology.
• National Institute of Biomedical Genomics (NIBMG), IndiamajorStrategic or Co-development PartnerCollaborated on the multicentric study to develop and validate GPSCAD (Genome-wide Polygenic Score for Coronary Artery Disease) using 6.6 million DNA variations in South Asian populations.
• Indian Healthcare Institutions (Narayana Hrudayalaya, Madras Medical Mission, Amrita Institute, Kovai Medical Center)majorStrategic or Co-development PartnerMultiple Indian hospitals including Narayana Hrudayalaya, Eternal Heart Care Centre, Narayana Health, Amrita Institute of Medical Sciences, Kovai Medical Center, and Madras Medical Mission collaborated on CAD PRS validation studies in Indian cohorts.
• UK BiobankmajorStrategic or Co-development PartnerSouth Asian UK Biobank data used in CAD PRS validation studies to assess genetic risk in South Asian populations living in the UK.
• International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)minorStrategic or Co-development PartnerCollaborated on CAD PRS validation study using Bangladeshi cohort data.
• Clinical Pharmacogenetics Implementation Consortium (CPIC)majorTechnology or IntegrationCuregen and Curegen Advanced pharmacogenomics tests are based on CPIC guidelines for drug-gene relationships, ensuring evidence-based clinical recommendations for personalized medication dosing.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MyHeritage: Global D2C DNA testing company with both ancestry and health offerings; competes in the same D2C funnel and overlaps on consumer genomics messaging.
• Ancestry: Large D2C DNA testing brand that has expanded from ancestry into health and wellness traits; comparable on the direct-to-consumer funnel, digital marketing, and one-time purchase model.
• Mapmygenome: Indian D2C genomics brand offering genetic tests for health, wellness, and pharmacogenomics; the closest India-based competitor and a near-direct comparable on geography, product mix, and customer base.
• Positive Bioscience: India- and Asia-focused personal genomics and preventive health testing company; comparable on South Asian customer base, D2C health-risk reporting, and PRS-style outputs.
• 23andMe: Global direct-to-consumer genetic testing leader offering health-risk and ancestry reports; the most direct comparable for Genessense's D2C PRS-based wellness model, though 23andMe is built primarily on European-ancestry data.

Emerging players

• Genomics PLC: UK-based PRS company building polygenic risk scores for healthcare systems and pharma; comparable on PRS methodology and population-level risk prediction, though B2B-focused rather than D2C.
• Helix: US-based population genomics and DNA-driven health platform that combines clinical-grade sequencing with D2C apps; comparable on NGS-based screening plus app-delivered results, though US-centric.
• Color Genomics: Clinical-grade genomics company offering hereditary cancer, cardiovascular, and pharmacogenomic panels; comparable on NGS-based hereditary cancer screening (Oncosense equivalent) and pharmacogenomics (Curegen equivalent).
• GeneDx: Clinical genomics company specializing in hereditary disease, rare disease, and carrier screening via NGS; comparable on the Oncosense/Carriergen-style hereditary cancer and carrier screening products.

Others

• MedGenome Labs Ltd. Parent company of Genessense and India's leading genetic diagnostics and genomics research firm with a CAP-accredited lab; included as a structural peer because Genessense shares lab, IP, and commercial infrastructure with MedGenome.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Genessense
• LinkedInlinkedin.com/company/medgenome

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genessense